← All causality assessments
Causality: well established
Causality assessment · Causality: well established
Vincristine (vinca alkaloids) and Peripheral neuropathy: is the FAERS signal real?
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Vincristine (vinca alkaloids) ↔ Peripheral neuropathy
n=645 co-reports · PRR 4.9 · ROR 5.0
Vincristine, a vinca-alkaloid chemotherapy drug, disrupts microtubules in nerve cells, producing a dose-limiting peripheral neuropathy — numbness, tingling, loss of reflexes, and sometimes painful weakness — that worsens with cumulative dosing and usually improves slowly after treatment ends. It is a direct consequence of the drug's mechanism and is a major reason doses are capped. The 645 co-reports (PRR 4.9) reflect both the real effect and the drug's central role in leukaemia and lymphoma regimens.
Regulatory basis: vincristine prescribing information (peripheral neuropathy warning; dose cap). Established vinca-alkaloid neuropathy literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Neuropathy develops and worsens with cumulative dosing and slowly improves after withdrawal |
| Strength | partial | PRR 5 on a moderate co-report count |
| Consistency | met | Reproduced across oncology practice |
| Specificity | met | A recognised vinca-alkaloid effect |
| Biological gradient | met | Cumulative-dose-related |
| Plausibility | met | Microtubule disruption in nerves is the mechanism |
| Coherence | met | Coheres with the labelled dose cap and monitoring |
| Experiment | partial | Dechallenge (withdrawal) usually leads to gradual improvement; no randomized trial |
| Analogy | met | Analogous to neuropathy from other vinca alkaloids and taxanes |
This page's own qualitative read, not an automated/citation-gated assessment.
✗ No ClinicalTrials.gov results-posting trial in the top search hits for vincristine captured peripheral neuropathy as a coded event; the toxicity is followed clinically during chemotherapy rather than recorded as a trial AE.